HOWL · Werewolf Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these condensed consolidated financial statements are issued in this Quarterly Report.”View the 10-Q filed Jul 31, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $32.91M | $44.83M | $56.43M | $41.78M | $53.76M | $35.27M | $16.64M | |
| $19.35M | $15.85M | $19.05M | $18.67M | $18.7M | $14.82M | $5.76M | |
| $52.26M | $60.68M | $75.48M | $60.45M | $72.46M | $50.09M | $22.4M | |
| -$31.26M | -$60.68M | -$73.59M | -$40.5M | -$56.06M | -$50.09M | -$22.4M | |
| $4.55M | $5.27M | $4.66M | $3.14M | $0 | — | — | |
| $1.97M | $3.11M | $6.67M | $7.42M | $1.91M | — | — | |
| -$3.36M | -$145K | $3.08M | $3.14M | $2.25M | $104K | $7.36M | |
| — | $0 | — | — | — | — | — | |
| -$34.61M | -$60.82M | -$70.52M | -$37.37M | -$53.81M | -$49.98M | -$15.04M | |
| -$56.27M | -$60.82M | -$70.52M | -$37.37M | -$53.81M | -$201.93M | -$28.22M | |
| USD/shares | — | -$1.32 | -$1.63 | -$1.05 | -$1.86 | -$10.94 | -$28.08 |
| USD/shares | — | -$1.33 | -$1.63 | -$1.05 | -$1.86 | -$10.94 | -$28.08 |
| shares | — | 46.02M | 43.33M | 35.65M | 28.86M | 18.46M | 1.01M |
| shares | — | 46.81M | 43.86M | 35.65M | 28.86M | 18.46M | 1.01M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 234 similar-size Biotechnology companies (of 520 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $0 | $1,885,000 | $19,943,000 |